Jane Chuprin

Aug 12, 2024 | digitalcommons.library.tmc.edu | Naema Nayyar |Jane Chuprin |Emily Sullivan |Mohini Singh

PURPOSE: Brain metastases are associated with high morbidity and are often resistant to immune checkpoint inhibitors. We evaluated whether CDK4/6 inhibitor (CDKi) abemaciclib can sensitize intracranial tumors to programmed cell death protein 1 (PD-1) inhibition in mouse models of melanoma and breast cancer brain metastasis. EXPERIMENTAL DESIGN: Treatment response was evaluated in vivo using immunocompetent mouse models of brain metastasis bearing concurrent intracranial and extracranial tumors.

Nov 4, 2023 | nature.com | Qi Tang |Hassan Fakih |Vignesh Hariharan |Ashley Summers |Ken Okamura |Kathryn R. Monopoli | +14 more

AbstractInhibition of Janus kinase (JAK) family enzymes is a popular strategy for treating inflammatory and autoimmune skin diseases. In the clinic, small molecule JAK inhibitors show distinct efficacy and safety profiles, likely reflecting variable selectivity for JAK subtypes. Absolute JAK subtype selectivity has not yet been achieved.